APML4 Protocol: A phase II trial in patients with previously untreated acute promyelocytic leukaemia to evaluate the effect on time to molecular relapse and early death rate as a result of: (i) adding arsenic trioxide to all-trans retinoic acid and idarubicin for remission induction, (ii) adding arsenic trioxide to all-trans retinoic acid as consolidation, (iii) the obligatory use of prednisone (or prednisolone) and aggressive haemostatic support during induction.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Arsenic trioxide (Primary) ; Tretinoin (Primary) ; Idarubicin; Prednisolone
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 09 Dec 2014 Status changed from active, no longer recruiting to completed according to an abstract presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
- 23 Jun 2011 New trial record